2. Cell Cycle/DNA Damage Metabolic Enzyme/Protease Immunology/Inflammation NF-κB Apoptosis Autophagy
  3. CDK Reactive Oxygen Species (ROS) Apoptosis Autophagy Caspase
  4. CDK6-IN-2

CDK6-IN-2 是一种 CDK6 共价抑制剂，IC50 为 0.013 μM。CDK6-IN-2 可抑制三阴性乳腺癌细胞的增殖、迁移，诱导细胞周期阻滞和凋亡 (apoptosis)。CDK6-IN-2 可通过细胞代谢重编程诱导 ROS 积累与线粒体损伤。CDK6-IN-2 具有抗肿瘤的活性，可用于三阴性乳腺癌的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CDK6-IN-2

CDK6-IN-2 Chemical Structure

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

CDK6-IN-2 相关抗体

Top Publications Citing Use of Products

查看 CDK 亚型特异性产品:

查看所有亚型
CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK11 CDK12 CDK13 CDK14 CDK16 CDK19 CDC CLK Pho85 CDK10 CDK15 CDK17 CDK18 CDK20 PITSLRE

查看 Caspase 亚型特异性产品:

查看所有亚型
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

CDK6-IN-2 is a CDK6 covalent inhibitor with an IC50 of 0.013 μM. CDK6-IN-2 inhibits the proliferation and migration of triple-negative breast cancer cells, and induces cell cycle arrest and apoptosis. CDK6-IN-2 induces ROS accumulation and mitochondrial damage through cellular metabolic reprogramming. CDK6-IN-2 exhibits anti-tumor activity and can be used for the research of triple-negative breast cancer[1].

IC50 & Target[1]

CDK6

0.013 μM (IC50)

Caspase 3

 

体外研究
(In Vitro)

CDK6-IN-2 (compound C32) (72 h) 可选择性抑制 TNBC 和 BRCA1 突变型乳腺癌细胞的活力，其 IC50 值 ≤ 0.08 μM，而对正常乳腺上皮细胞和 ER 阳性乳腺癌细胞的活性较低[1]。
CDK6-IN-2 (0-0.2 μM; 0-72 h) 可强效抑制 MDA-MB-231 和 BT-549 三阴性乳腺癌 (TNBC) 细胞增殖、迁移，诱导细胞凋亡、细胞周期阻滞和细胞内 ROS 累积[1]。
CDK6-IN-2 (0-0.20 μM; 72 h) 可在 MDA-MB-231 和 BT-549 三阴性乳腺癌 (TNBC) 细胞中诱导线粒体损伤与功能异常，包括膜电位降低和结构异常[1]。
CDK6-IN-2 (0-0.20 μM; 72 h) 可抑制 MDA-MB-231 和 BT-549 三阴性乳腺癌 (TNBC) 细胞中的自噬流与降解过程，LC3II 和 P62 蛋白的共同积累可证明这一点[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CDK6-IN-2 相关抗体:

Cell Viability Assay[1]

Cell Line: Triple-negative breast cancer (TNBC) lines MDA-MB-231, MDA-MB-468, BT-549; BRCA1-mutant line MDA-MB-436; ER-positive line MCF-7; normal mammary epithelial line MCF-10A
Concentration: /
Incubation Time: 72 h
Result: Selectively inhibited the viability of TNBC and BRCA1-mutant breast cancer cells with IC50 values of 0.06 μM (MDA-MB-231), 0.08 μM (MDA-MB-468), 0.04 μM (BT-549), and 0.06 μM (MDA-MB-436).
Showed reduced activity against non-TNBC cells with IC50 = 0.39 μM (MCF-7), 2.30 μM (MCF-10A).

Cell Proliferation Assay[1]

Cell Line: TNBC cell lines MDA-MB-231 and BT-549
Concentration: MDA-MB-231: 0.1, 0.15, 0.2 μM; BT-549: 0.08, 0.12, 0.16 μM
Incubation Time: 72 h
Result: Concentration-dependently reduced the number of EdU-positive proliferating cells in both TNBC lines.

Cell Cycle Analysis[1]

Cell Line: TNBC cell line MDA-MB-231
Concentration: 0.10, 0.15, 0.20 μM
Incubation Time: 72 h
Result: Induced a concentration-dependent S-phase cell cycle arrest, with the proportion of S-phase cells increasing from 35.91% (control) to 40.68% (0.10 μM), 48.31% (0.15 μM), and 55.9% (0.20 μM), while the proportion of G0/G1-phase cells decreased correspondingly.
药代动力学
(Parmacokinetics)
Species Dose Route C0 AUC0-t AUC0-∞ T1/2 Vd/F CL/F
Rat[1] 2 mg/kg i.v. 772.60 ng/mL 82.75 ng·h/mL 93.80 ng·h/mL 0.59 h 13.09 L/kg 15.46 L/h/kg
体内研究
(In Vivo)

CDK6-IN-2 (10-20 mg/kg; i.p.; daily; 18 days) 可剂量依赖性地抑制 BALB/c 裸鼠体内 MDA-MB-231 肿瘤的生长[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c nude (female, 4 weeks old, subcutaneous inoculation of 1×107 MDA-MB-231 cells)[1]
Dosage: 10 mg/kg; 20 mg/kg
Administration: i.p.; daily; 18 days
Result: Reduced mean tumor weight to 0.68 g (10 mg/kg group) and 0.23 g (20 mg/kg group), significantly lower than the control group's 1.45 g.
Significantly down-regulated Ki67, CDK6, and RB1 positive cell counts in treated tumor tissues.
Significantly up-regulated Cleaved Caspase-3 positive cell counts in treated tumor tissues.
Caused no significant changes in mouse body weight.
Showed no pathological damage to major organs (heart, liver, spleen, lung, kidney) via H&E staining.
分子量

529.43

Formula

C24H29BrN6O3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
参考文献

CDK6-IN-2 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

CDK6-IN-2CDKReactive Oxygen Species (ROS)ApoptosisAutophagyCaspaseCyclin dependent kinasetriple-negative breast cancer cellsBRCA1-mutant breast cancer cellsCDK6ROStriple-negative breast cancerapoptosisMDA-MB-231Inhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
CDK6-IN-2
目录号：
HY-181483
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z